Injectable hydrogel as well as preparation method and application thereof

By combining oxidized hyaluronic acid, 4-aminophenylboronic acid and rosemary acid with lithium magnesium silicate, AOHA-RA/Lap hydrogel is formed, and the problem of integrating antibacterial, immune regulation and promoting bone differentiation components is solved, and the problem of achieving the Effective repair of infectious bone defects.

CN119034006AActive Publication Date: 2024-11-29ZHONGNAN HOSPITAL OF WUHAN UNIV
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411204637.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-29
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The prior art is difficult to integrate components with antibacterial, immune regulation and bone differentiation into injectable hydrogels for the treatment of infectious bone defects.

Method used

Oxidized hyaluronic acid, 4-aminophenylboronic acid and rosmarinic acid are combined with lithium magnesium silicate, and reversible Schiff base bonds and borate ester bonds are formed through Schiff base reaction to form AOHA-RA with self-enhanced characteristics. /Lap hydrogel.

Benefits of technology

The hydrogel continuously releases rosemary acid and lithium magnesium silicate in the body, building an antibacterial, osteoinducible and immune-regulated osteogenic microenvironment, significantly accelerating the repair of infectious bone defects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119034006A_ABST
    Figure CN119034006A_ABST
Patent Text Reader

Abstract

The invention provides injectable hydrogel as well as a preparation method and application thereof, and the method comprises the following steps: oxidizing hyaluronic acid to obtain oxidized hyaluronic acid, and adding deionized water to prepare an oxidized hyaluronic acid solution; adding 4-aminophenylboronic acid into the oxidized hyaluronic acid solution, uniformly stirring to obtain AOHA, and adding deionized water to prepare an AOHA solution; and adding rosmarinic acid and magnesium lithium silicate into the solution containing AOHA, uniformly mixing and reacting to obtain the injectable hydrogel. The hydrogel has good immunoregulation function, osteogenesis induction, biocompatibility and antibacterial property, and can be used for treating infectious bone defects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of orthopedic implant materials, and in particular to an injectable hydrogel and a preparation method and application thereof. Background Art

[0002] Infected bone defects are common orthopedic diseases after open bone trauma and are an important problem faced by clinical surgeons. Due to the invasion of local pathogens and the subsequent lack of blood supply, the spread of necrotic tissue, and the apoptosis of osteoblasts, the osteogenic capacity of the infected bone defect site is usually severely reduced, resulting in delayed bone healing. Therefore, it has been considered the most reasonable strategy to treat infected bone defects by targeting bacteria and bone marrow stromal cells (BMSCs), eliminating in situ pathogen infection, and constructing an osteogenic microenvironment at the bone defect interface. With the progress of osteoimmunology, the key role of immune regulation in bacterial clearance and bone healing has been gradually elucidated. Among them, macrophages are one of the most important effector cells of immune response, which can secrete a variety of cytokines to directly affect initial inflammation, BMSCs recruitment, and subsequent differentiation and mineralization. Therefore, biomaterials that have antibacterial properties, promote macrophage M2 polarization, and induce BMSCs osteogenic differentiation will be expected to further accelerate the repair of infected bone defects.

[0003] Rosmarinic acid (RA) is a natural phenolic compound found in many plants such as Boraginaceae and Lamiaceae, with an ester structure of caffeic acid and 3,4-dihydroxyphenyllactic acid. RA not only has a broad-spectrum antibacterial activity, but also has the potential to induce macrophage M2 polarization. Lithium magnesium silicate (Lap) is a synthetic clay composed of disc-shaped crystals (about 25nm in diameter and 0.92nm in height). A 2% Lap aqueous solution can mediate the self-assembly of Lap crystals to form a thixotropic hydrogel. Studies have shown that even in the absence of exogenous growth factors such as BMP-2, Lap can be activated in vivo through its degradation product Mg 2+ 、Si(OH)4、Li + It can upregulate the expression of bone-related genes and promote the synthesis of type I collagen, thereby promoting bone formation.

[0004] In recent years, injectable hydrogels have been widely used in the field of tissue engineering. They can replace implantation surgery with minimally invasive injection methods and can be formed into any desired shape to match irregular defects. Therefore, injectable hydrogels with high structural adaptability, minimal invasiveness, tissue similarity, and drug delivery capabilities are considered to be ideal candidate materials for repairing infected bone defects. However, how to integrate the above-mentioned antibacterial, immunomodulatory, and osteodifferentiation-promoting components into injectable hydrogels remains a huge challenge. Summary of the invention

[0005] The purpose of the present invention is to provide an injectable hydrogel and a preparation method and application thereof. The hydrogel has good immunomodulatory function, osteogenic induction, biocompatibility and antibacterial properties and can be used to treat infected bone defects.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] In a first aspect of the present invention, a method for preparing an injectable hydrogel is provided, the method comprising:

[0008] Oxidizing hyaluronic acid to obtain oxidized hyaluronic acid, and adding deionized water to prepare an oxidized hyaluronic acid solution;

[0009] Adding 4-aminophenylboronic acid to the oxidized hyaluronic acid solution, stirring evenly to obtain AOHA, and adding deionized water to prepare an AOHA solution;

[0010] Add rosmarinic acid and lithium magnesium silicate into the solution containing AOHA and mix them evenly to obtain an injectable hydrogel.

[0011] Furthermore, in the oxidized hyaluronic acid solution, the molar ratio of the oxidized hyaluronic acid to deionized water is 1.5:1-10:1.

[0012] Furthermore, the ratio of the amount of the 4-aminophenylboronic acid to the amount of the oxidized hyaluronic acid is 1:5-4:5.

[0013] Furthermore, in the AOHA solution, the molar ratio of the AOHA to deionized water is 1:50-1:20.

[0014] Furthermore, the concentration of rosmarinic acid added to the solution containing AOHA is 25-50 mg / ml.

[0015] Furthermore, the molar ratio of the rosmarinic acid to the AOHA is 1:2-1:10, and the molar ratio of the lithium magnesium silicate to the AOHA is 3:1-5:1.

[0016] In a second aspect of the present invention, an injectable hydrogel prepared by the method is provided.

[0017] In the third aspect of the present invention, there is provided the use of the injectable hydrogel in preparing a material for repairing infected bone defects.

[0018] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0019] 1. The injectable hydrogel of the present invention is prepared by connecting oxidized hyaluronic acid with 4-aminophenylboronic acid through a Schiff base reaction, and then loading rosmarinic acid into the system as a drug, and lithium magnesium silicate provides an alkaline environment to the system to form a first-level network, and then the "card-worker" structure of lithium magnesium silicate itself forms a second-level network to enhance the first-level network. Due to the reversibility of Schiff base bonds, borate bonds and electrostatic interactions, AOHA-RA / Lap hydrogel is not only injectable, but also exhibits self-reinforcement properties after shear thinning.

[0020] After the injectable hydrogel of the present invention is implanted into the infected bone defect site of rats, rosmarinic acid and lithium magnesium silicate can be continuously released for a long time, and an osteogenic microenvironment with antibacterial, bone-inducing and immunomodulatory functions is constructed on the defect interface, thereby achieving the effect of repairing the infected bone defect.

[0021] 2. In the past, the treatment of infected bone defects was aimed at bacteria and BMSCs. The present invention utilizes the immunomodulatory effect of rosmarinic acid, combined with its antibacterial effect and the osteogenic induction function of lithium magnesium silicate, thus achieving a three-in-one therapeutic effect.

[0022] 3. The present invention utilizes the alkalinity of lithium magnesium silicate to provide conditions for the successful construction of the primary network of the hydrogel, and at the same time cleverly utilizes the structure of lithium magnesium silicate itself to form a secondary network and enhance the primary network. The hydrogel exhibits self-reinforcement properties after shear thinning, so that it can adaptively fit the bone defect interface after injection in vivo. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings in the following description are some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.

[0024] Figure 1 is a schematic diagram of the synthesis of AOHA-RA / Lap injectable hydrogel;

[0025] Figure 2 This is a picture of the AOHA-RA / Lap injectable hydrogel and its effect of filling bone defects in vitro; Figure 2 A is the AOHA-RA / Lap hydrogel injection diagram. Figure 2 B is a real picture of AOHA-RA / Lap injectable hydrogel. Figure 2 C is the actual picture of AOHA-RA / Lap hydrogel at the bone defect interface

[0026] Figure 3is the rheological diagram of AOHA-RA / Lap injectable hydrogel; Figure 3 A is the Lap rheology diagram of the frequency mode, Figure 3 B is the AOHA-RA rheological diagram of the frequency mode, Figure 3 C is the AOHA-RA / Lap rheology diagram of the frequency mode, Figure 3 D is the AOHA-RA / Lap rheogram before the application of shear force in the time mode, Figure 3 E is the AOHA-RA / Lap rheology diagram after applying shear force in time mode

[0027] Figure 4 This is the electron microscopy morphology of the AOHA-RA / Lap injectable hydrogel;

[0028] Figure 5 is the biocompatibility result of AOHA-RA / Lap injectable hydrogel; among them, Figure 5 A is the live and dead cell staining of RAW264.7 cells after 3 days of different treatments. Figure 5 B shows live and dead cell staining of BMSCs cells 3 days after receiving different treatments.

[0029] Figure 6 It is the result of AOHA-RA / Lap injectable hydrogel regulating macrophage polarization;

[0030] Figure 7 It is the result of AOHA-RA / Lap injectable hydrogel regulating the osteogenic differentiation of BMSCs;

[0031] Figure 8 These are the in vitro antibacterial results of AOHA-RA / Lap injectable hydrogel;

[0032] Fig. 9 The micro-CT results of AOHA-RA / Lap injectable hydrogel in repairing infected bone defects in vivo. DETAILED DESCRIPTION

[0033] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0034] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0035] The general idea of ​​the present invention is as follows:

[0036] The invention discloses a multifunctional injectable hydrogel for repairing infectious bone defects and a preparation method thereof. A one-pot method is used to mix oxidized hyaluronic acid (OHA), 4-aminophenylboronic acid (4-APBA) and rosmarinic acid (RA), and then lithium magnesium silicate (Lap) is added to synthesize the AOHA-RA / Lap injectable hydrogel.

[0037] AOHA-RA / Lap hydrogel exhibits self-reinforcement properties after shear thinning, and has the functions of antibacterial, promoting macrophage M2 polarization, and inducing osteogenic differentiation of bone marrow mesenchymal stem cells.

[0038] After AOHA-RA / Lap hydrogel is injected into the bone defect site, it can fit well with the bone defect interface; as the borate bonds gradually break, AOHA-RA / Lap hydrogel can continuously release rosmarinic acid and lithium magnesium silicate for a long time.

[0039] Therefore, an osteogenic microenvironment with antibacterial, osteoinductive and immunomodulatory functions was constructed at the defect-hydrogel interface to achieve the repair of infected bone defects.

[0040] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.

[0041] The present application will be described in detail below with reference to embodiments and experimental data.

[0042] Example 1. Preparation method of AOHA-RA / Lap injectable hydrogel

[0043] 1. Preparation of OHA: Dissolve 2g of sodium hyaluronate (HA) in 50ml of deionized water, stir in a magnetic stirring water bath at 600r / min for 3 hours until dissolved, add 1.3g of sodium periodate after cooling to room temperature, stir in a water bath at 25℃ for 12 hours, then add ethylene glycol to quench the unreacted sodium periodate, and continue stirring for 1 hour. Then put the product into a dialysis bag with a cutoff of 3500D and dialyze for 48 hours. Change the water every four hours on the first day, and then change the water twice a day for a total of three days, and then freeze-dry to successfully prepare OHA ( Figure 1 ).

[0044] 2. Prepare AOHA solution: weigh 0.2 g of OHA and dissolve it in 1 ml of deionized water. Let it stand until it is completely dissolved. Add 0.05 g of 4-APBA and stir it on a magnetic stirrer at 25°C for 24 hours. Then dialyze it for 3 days. The resulting solution is freeze-dried to obtain AHOA.

[0045] 3. Preparation of AOHA-RA / Lap injectable hydrogel: Weigh 0.2 g of AOHA and dissolve it in 1 ml of deionized water. Let it stand until it is completely dissolved. Add 0.025 g of RA and 0.1 g of Lap to the AOHA solution, stir evenly on a magnetic stirrer, and let it stand to obtain AOHA-RA / Lap hydrogel.

[0046] Example 2. Characterization of AOHA-RA / Lap injectable hydrogel

[0047] Place the hydrogel in a syringe, such as Figure 2 As shown in the figure, the newly synthesized composite hydrogel is in a viscous flow state; after standing, the viscous flow state changes into a gel state. The hydrogel is injected into the irregular bone defect with a needle. Due to its injectable properties, the hydrogel can gel in situ and can fit the complex shape of the bone defect. The rheological properties of the hydrogel are tested using a rheometer, such as Figure 3 As shown in the figure, in the frequency mode, the hydrogel storage modulus G' is greater than the corresponding loss modulus G", and in the time mode, the hydrogel can gel within 2 minutes, and the subsequent state is stable, which further proves the properties of the gel. Then, a JSM-7500F scanning electron microscope was used to photograph the surface of the hydrogel material, as shown in the figure. Figure 4 As shown, the material surface exhibits a loose and porous structure, which is conducive to drug loading and cell migration and proliferation.

[0048] Example 3. Biocompatibility of AOHA-RA / Lap injectable hydrogel

[0049] Calcein-AM / PI live-dead cell staining kit was used to evaluate the cytocompatibility of the hydrogel in BMSCs or RAW264.7. BMSCs or RAW264.7 cells (10 cells per well) were placed in the 5 ) were seeded in a 6-well plate, and the AOHA-RA / Lap hydrogel was placed in a transwell chamber. After 72 hours of culture, the dead cells and live cells were stained according to the instructions. Figure 5 As shown, the BMSCs and RAW264.7 cells in the blank control group and AOHA-RA / Lap hydrogel group survived well, and no obvious dead cells were observed.

[0050] Example 4: Effect of AOHA-RA / Lap injectable hydrogel on polarization of RAW264.7 cells in vitro

[0051] RAW264.7 cells were co-cultured with AOHA-RA / Lap hydrogels (placed in transwell chambers) in complete medium for 3 days. LPS was added during the process (to promote M1 polarization), and the cells were immunofluorescently stained for iNOS (M1 surface marker) and CD206 (M2 surface marker). Cells without hydrogels were used as blank controls, and cells with only LPS added were used as positive controls. Figure 6 As shown, compared with the blank control group, the expression of iNOS in the LPS group cells increased, but the expression of iNOS in the AOHA-RA / Lap hydrogel group cells was significantly reduced compared with the LPS group. In addition, the expression of CD206 in the AOHA-RA / Lap hydrogel group cells was also significantly higher than that in the blank control and LPS groups.

[0052] Example 5: Effect of AOHA-RA / Lap injectable hydrogel on osteogenic differentiation of BMSCs in vitro

[0053] BMSCs were co-cultured with AOHA-RA / Lap hydrogel (placed in a transwell chamber) in osteogenic induction medium for 7 days, and ALP staining was performed using an alkaline phosphatase (ALP) staining kit. Cells without hydrogel were used as blank controls. On the 14th day of osteogenic induction, the degree of calcium deposition in the extracellular matrix of BMSCs was evaluated by Alizarin red (ARS) staining. Figure 7 As shown, the ALP activity of BMSCs in the AOHA-RA / Lap hydrogel group on day 7 and the degree of extracellular matrix calcium deposition on day 21 were higher than those in the blank control group.

[0054] Example 6: In vitro antibacterial ability of AOHA-RA / Lap injectable hydrogel

[0055] AOHA-RA / Lap hydrogel (50 mg) was added into 1 mL of Escherichia coli or Staphylococcus aureus suspension (10 7 CFU / mL), and the Escherichia coli or Staphylococcus aureus suspension co-cultured without hydrogel was used as the control, and cultured in a 24-well plate at 37°C for 12 hours. Then 10 μL of the bacterial solution was taken, diluted with 500 μL PBS, and evenly applied on the surface of the agar plate. After incubation at 37°C for 12 hours, the colonies were counted. Figure 8 As shown, the number of Escherichia coli or Staphylococcus aureus colonies on the agar plate of the AOHA-RA / Lap hydrogel group was extremely small, indicating that AOHA-RA / Lap hydrogel had strong bactericidal activity against Escherichia coli or Staphylococcus aureus.

[0056] Example 7: Treatment of rat infected skull defect model

[0057] The rat infected skull defect model was created using Staphylococcus aureus, and AOHA-RA / Lap hydrogel was implanted 2 weeks after surgery. Four and eight weeks after hydrogel implantation, the rats were killed and the skulls were removed and fixed in 4% paraformaldehyde solution. The bone defect area was scanned using a micro-CT system to evaluate the formation of new bone. Fig. 9 As shown in the figure, 4 weeks after hydrogel implantation, the skull of the blank control group showed almost no new bone formation due to Staphylococcus aureus infection, which led to bone destruction. In contrast, new bone was clearly visible in the AOHA-RA / Lap hydrogel group. 8 weeks after hydrogel implantation, the skull bone regeneration of rats in the AOHA-RA / Lap hydrogel group was more obvious, and the skull defect was almost completely filled with new bone, while only a small amount of new bone regeneration was seen in the blank control group.

[0058] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0059] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0060] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A method for preparing an injectable hydrogel, characterized in that: The method comprises: Oxidizing hyaluronic acid to obtain oxidized hyaluronic acid, and adding deionized water to prepare an oxidized hyaluronic acid solution; Adding 4-aminophenylboronic acid to the oxidized hyaluronic acid solution, stirring evenly to obtain AOHA, and adding deionized water to prepare an AOHA solution; Add rosmarinic acid and lithium magnesium silicate into the solution containing AOHA and mix them evenly to obtain an injectable hydrogel.

2. The method for preparing the injectable hydrogel according to claim 1, characterized in that: In the oxidized hyaluronic acid solution, the molar ratio of the oxidized hyaluronic acid to deionized water is 1.5:1-10:

1.

3. The method for preparing the injectable hydrogel according to claim 1, characterized in that: The ratio of the amount of the 4-aminophenylboronic acid to the amount of the oxidized hyaluronic acid is 1:5-4:

5.

4. The method for preparing the injectable hydrogel according to claim 1, characterized in that: In the AOHA solution, the molar ratio of the AOHA to deionized water is 1:50-1:

20.

5. The method for preparing the injectable hydrogel according to claim 1, characterized in that: The concentration of rosmarinic acid added to the solution containing AOHA is 25-50 mg / ml.

6. The method for preparing the injectable hydrogel according to claim 1, characterized in that: The molar ratio of the rosmarinic acid to the AOHA is 1:2-1:10, and the molar ratio of the lithium magnesium silicate to the AOHA is 3:1-5:

1.

7. An injectable hydrogel prepared according to the method according to any one of claims 1 to 6.

8. Use of the injectable hydrogel according to claim 7 in preparing materials for repairing infected bone defects.

Citation Information

Patent Citations

  • Dynamic polymer material and application thereof

    CN107129580A

  • High-strength electric response lubricating hydrogel imitating cornea and preparation method thereof

    CN110204742A

  • 3D bioprinting ink, preparation method of ink, tissue engineering scaffold and preparation method of scaffold

    CN110665063A

  • Antibacterial hydrogel as well as preparation method and application thereof

    CN115160601A

  • Cartilage tissue repair hydrogel and preparation method thereof

    CN116285386A